Drug Discovery World

JULY 17, 2023

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine will start of a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases.

Therapies 130

Therapies Small Molecule DNA Clinical Trials 130

DrugBank

MAY 15, 2024

Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. Among these targets are proteins, receptors, and enzymes that are fundamental to disease mechanisms.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

DrugBank

MAY 22, 2024

These tough nuts to crack in medical science—biological targets known to play roles in diseases but resistant to traditional drug design—are now seeing new strategies that shift the paradigm from "undruggable" to "druggable." Beyond Proteins: DNA and RNA Frontier The story doesn’t end with proteins.

Small Molecule 67

Small Molecule RNA DNA Pharmaceutical Companies 67

Covalent Modifiers

DECEMBER 11, 2023

Mutations that impair nuclear protein association with chromatin are implicated in numerous diseases. Covalent ligands are a promising strategy to pharmacologically target nuclear proteins, such as transcription factors, which lack ordered small-molecule binding pockets. TurboID (His-TID) construct, with chemoproteomics.

Small Molecule 59

Small Molecule DNA Regulations Disease 59

Drug Discovery World

DECEMBER 21, 2023

Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker. Read the article – Expert view: What’s next for cell and gene therapy?

FDA Approval 147

FDA Approval Therapies Small Molecule Clinical Trials 147

Drug Hunter

MAY 18, 2023

researching DNA photoproducts related to skin cancer. As the ADC team moved toward a greater emphasis on development, Dian felt the pull to return to her “research mindset” and switched paths again, this time delving into DMPK, particularly small molecules and peptides. “I Proteomics!

Small Molecule 131

Small Molecule DNA Pharmacokinetics Engineering 131

Drug Discovery World

AUGUST 10, 2023

RA: How is Totus Medicines attempting to target untreatable or undruggable diseases? If you can buy 100,000 times the number of tickets – or screen 100,000 times as many therapeutic molecules – you’re going to win a lot more and a lot faster. RA: What have been some of the long-term challenges in targeting harder to treat diseases?

Small Molecule 130

Small Molecule Clinical Trials Disease Cell Biology 130

Drug Target Review

JULY 18, 2024

We believe liquid biopsy is very helpful for oncology drug development because the reduction and clearance of circulating DNA occurs quickly before radiographic imaging is available. The initial techniques were able to detect circulating tumour DNA in patients who already had metastatic spread. Reference 1 Pant, S., Wainberg, Z.A.,

Drug Development 59

Drug Development Clinical Trials Drugs Small Molecule 59

Drug Target Review

NOVEMBER 6, 2023

Advances in disease understanding and combination strategies in haematology We now know that blood cancers are characterised by molecular and phenotypic heterogeneity. These regimens frequently include one or two small molecule inhibitors and immuno-oncology (IO) therapies, such as monoclonal antibodies and T-cell engagers.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. This is because many proteins do not have small-molecule binding sites. This is not the first deal for RNA therapeutics for Genentech.

RNA 52

RNA Small Molecule DNA Licensing 52

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Executive Vice President, Research, Gilead Sciences. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

LifeSciVC

AUGUST 5, 2024

In fact, drug discovery scientists today would be hard pressed to do their jobs without access to a wealth of well-annotated human genome sequences and their association with specific diseases for target selection through to translational medicine. One final parallel to 2001.

Molecular Biology 90

Molecular Biology Production Small Molecule Drug Development 90

LifeSciVC

DECEMBER 6, 2022

HotSpot Therapeutics today announced a strategic collaboration with Abbvie to develop IRF5 transcription factor inhibitors for autoimmune diseases. These hair clip-like molecules clamp onto DNA, thereby turning many genes on and off.

Small Molecule 40

Small Molecule DNA Regulations Science 40

Drug Discovery World

JANUARY 3, 2023

Matthew Clark , CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Artificial intelligence.

DNA 130

DNA Targeted Protein Degradation Small Molecule Pharma Companies 130

Drug Discovery World

JUNE 5, 2023

Showcase agenda Throughout the day, there were a number of presentations on the exhibition floor which provided company updates and showcased a number of exciting results and projects, highlighting both how far we have come in the treatment of disease, as well as how far there is still to go.

Small Molecule 130

Small Molecule Treatment Science Disease 130

Drug Target Review

JUNE 19, 2024

The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. Just like small molecules and antibodies, cell therapies are changing how we treat patients.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

PLOS: DNA Science

JUNE 22, 2023

A “DNA damage checkpoint” rests the cell cycle while special proteins repair damaged DNA. The candidate drug, vorasidenib, is a small molecule that inhibits survivin. Cancer cells make too much survivin, with levels increasing as the disease spreads and becomes more aggressive.

Drugs 52

Drugs Small Molecule DNA Bioethics 52

Drug Discovery World

SEPTEMBER 9, 2024

This capability enables their use in various bioinformatics and cheminformatics applications, including predicting DNA regulatory elements and optimising drug properties. This expands the range of explorable chemical space, opening up new avenues for discovering molecules that could potentially address difficult-to-treat diseases.

Drugs 162

Drugs Bioinformatics Computational Chemistry International 162

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Science 100

Science Drugs FDA Engineering 100

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Discovery World

NOVEMBER 17, 2022

It is believed that the term synthetic biology was created in 1970 by geneticist, Waclaw Szybalski 1 as work was being carried out on the development of DNA sequencing and synthesis techniques. In the UK, work being carried out at Imperial College 4 has seen the engineering of designer cells which could help advance treatment for disease. .

Engineering 130

Engineering Molecular Biology Synthetic Chemistry DNA 130

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

LifeSciVC

MARCH 1, 2023

Augustin et al summarized how novel platforms have more recently been applied to try to solve this question including CRISPR genome editing combined with adoptive cell therapy, siRNA knockdown, DNA encoded library approaches and machine learning algorithms.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

Drug Target Review

JULY 18, 2023

“I think it is astonishing that The Human Genome Project was completed exactly 20 years ago and DNA was discovered by Franklin and published by Watson and Crick exactly 70 years ago, yet that 10 percent success rate has still not improved. This means that we are not doing something right.

Drug Development 98

Drug Development Drugs Pharmaceutical Companies Clinical Development 98

The Pharma Data

MARCH 7, 2022

The approach will allow researchers to understand the role individual genes play in normal cell growth and development, in aging, and in such diseases as cancer, said Shiri Levy, a postdoctoral fellow in UW Institute for Stem Cell and Regenerative Medicine (ISCRM) and the lead author of the paper. it can be reawakened.

RNA 52

RNA DNA Packaging Small Molecule 52

Drug Discovery World

APRIL 15, 2023

Kintara Therapeutics to present two posters on treatment of recurrent glioblastoma Kintara Therapeutics is a clinical-stage biotechnology company dedicated to the development of unique and novel cancer therapies for patients who are failing or resistant to current treatment regimens, using its lead asset VAL-083. VAL-083, is a ‘first-in-class’ small-molecule (..)

Virus 130

Virus Clinical Trials Trials Therapies 130

The Pharma Data

NOVEMBER 18, 2020

In addition, OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients a durable stable disease status. We look forward to providing updates of our study, which we believe could offer potential therapeutic benefits to patients suffering from lung cancer.” Forward-Looking Statements.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 13, 2020

Silmitasertib is a first-in-class small molecule drug that targets CK2 and acts as a CK2-inhibitor. In July 2020 , Silmitasertib was granted Rare Pediatric Disease Designation to treat Medulloblastoma by the U.S. TAIPEI and SAN DIEGO , Dec. 13, 2020 /PRNewswire/ — Senhwa Biosciences, Inc. About Silmitasertib.

Small Molecule 40

Small Molecule FDA DNA Clinical Trials 40

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

JANUARY 21, 2021

Silmitasertib is a first-in-class small molecule drug that targets CK2 and acts as a CK2-inhibitor. In July 2020 , Silmitasertib was granted Rare Pediatric Disease Designation (RPD) to treat Medulloblastoma by the U.S. TAIPEI and SAN DIEGO , Jan. 21, 2021 /PRNewswire/ — Senhwa Biosciences, Inc. About Silmitasertib.

Trials 52

Trials Treatment Small Molecule Hospitals 52

The Pharma Data

APRIL 11, 2023

Both small molecule inhibitors in Immuno-Oncology are being jointly developed in a strategic research alliance with the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumors was initiated and is currently enrolling patients.

Research 40

Research Clinical Trials Small Molecule Pharmacokinetics 40

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . billion, compared to $19.9 Tuyen Ong, MD, CEO, Ring Therapeutics. .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

The Pharma Data

DECEMBER 14, 2020

It is considered an orphan disease for which there is no cure. The current standard of care for GBM consists of de-bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ). The global GBM treatment market is projected to reach $3.3

DNA 52

DNA Clinical Trials Drugs Therapies 52

Drug Discovery World

APRIL 30, 2024

Whilst research into mRNA has been ongoing for decade, interest has sparked in recent years and research has begun to expand into areas of vaccinology, infectious diseases and other indications. If the body fails to make the right protein, diseases such as cancer, type II diabetes, neurological conditions, and metabolic diseases can occur.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

OCTOBER 17, 2023

DDW Editor Reece Armstrong speaks to Benedikt Nilges , Head of Technology and Data Analytics at OMAPiX about spatial biology’s use in drug discovery and bettering our understanding of disease. RA: How does spatial biology enhance our understanding of the human body and associated diseases?

Disease 130

Disease Small Molecule Drugs RNA 130

Codon

AUGUST 27, 2024

Allison Berke makes the case for real-time DNA sequencing and AI tools to detect pathogens before they spread widely. Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. After copying the DNA to form a big pool, each piece is sequenced.

DNA 90

DNA Hospitals Laboratories Virus 90

Drug Discovery World

JULY 8, 2024

For decades, the life sciences community held the belief that RNA was merely the intermediary messenger (mRNA) between DNA and protein, a dogma that has been the foundation of biology. By silencing transthyretin (TTR) mRNA, patisiran decreases the production of TTR protein, the molecule responsible for causing the disease.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147